A new study has found that the second dose of the Pfizer vaccine produces a 3.5-times greater antibody response when given at 12 weeks, compared to three weeks.
On Wednesday (12 May), the CDC announced that the Pfizer vaccine could now be given to 12-15 year olds - effective immediately for 17 million adolescents.
Adam Enterkin, Global SVP Sales at BlackBerry, explores the critical role of secure crisis communications for the vaccine rollout and the value of a communication strategy to combat misinformation.
Researchers from Northwestern Medicine have studied the placentas from patients who received the COVID-19 vaccine during pregnancy and found no evidence of damage.
Dr Babita Agrawal, Professor at the University of Alberta, discusses both the vital present and future roles of vaccines and immunotherapeutics in combatting COVID-19.
Rachel Thrasher, Research Fellow at the Global Development Policy Center in Boston, explains how the new US stance could change the TRIPS waiver debate.
New data explores why some in the UK continue to experience vaccine hesitancy - with one man explaining that "it is human nature to have second thoughts".
The Joint Committee on Vaccination and Immunisation (JCVI) has advised that all under 40s should be offered an alternative to the Oxford/AstraZeneca vaccine following blood clot risk.
The European Commission on Thursday (6 May) responded to a US declaration of support for the TRIPS waiver, stating that they were open to further discussions without explicit agreement.
The CureVac mRNA vaccine is currently in final stages of clinical trials - but it is expected to perform like Pfizer and Moderna, with the bonus of surviving at ordinary refrigeration temperatures.
